CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement for Octreotide Long Acting Injectable (LAI) Microsphere for Neuroendocrine Cancers and Acromegaly

ROCKVILLE, Md. and BEIJING, Nov. 7, 2019 -- (Healthcare Sales & Marketing Network) -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products... Biopharmaceuticals, Oncology, Licensing, Distribution CASI Pharmaceuticals, Pharmathen Global, octreotide
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news